Overview
Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation
Status:
Recruiting
Recruiting
Trial end date:
2030-10-01
2030-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Atrial fibrillation (AF) is progressively common, and increases the risk of stroke five-fold. Oral anticoagulation is the mainstay therapy; however, it increases the risk of bleeding. Moreover, 30% with AF and at risk of stroke are not in relevant anticoagulation. The randomized PROTECT-AF trial has demonstrated the superiority of left atrial appendage occlusion (LAAO) as compared to warfarin for prevention of the combined endpoint of stroke, major bleeding and cardiovascular mortality. However, studies comparing LAAO to therapy with novel oral anticoagulants (NOAC) have not been carried out. This study aims to assess the effect of left atrial appendage occlusion (LAAO) to reduce the incidence of stroke, systemic embolism, major bleeding and all-cause mortality in patients with atrial fibrillation (AF) and a prior ischemic stroke or transient ischemic attack (TIA).Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
University of AarhusCollaborators:
Aalborg Universitetshospital
Aalborg University Hospital
Aarhus University Hospital
Haukeland University Hospital
Helsinki University Central Hospital
Karolinska University Hospital
Odense University Hospital
Sahlgrenska University Hospital, Sweden
Turku University HospitalTreatments:
Apixaban
Dabigatran
Edoxaban
Rivaroxaban
Criteria
Inclusion Criteria:- Age ≥ 18 years
- documented non-valvular atrial fibrillation (paroxysmal, persistent or permanent)
- Eligible for long-term Novel Oral Anticoagulation (NOAC) therapy
- Ischemic stroke within the recent 6 months verified by neuroimaging, or
- Transient ischemic attack within 6 months with proven cerebral ischemia based on
cerebral magnetic resonance imaging (MRI)
Exclusion Criteria:
- Modified rankin scale > 3 at time of enrollment
- Glomerular filtration rate (GFR) below 15 ml/min/1.73 m2
- Contraindication towards long-term aspirin therapy
- Planned combined cardiovascular interventional procedures at the time of enrollment
- Terminal illness or cancer with life expectancy less than 2 years.